Novartis AG ADR (NVS)vsMeridian Bioscience Inc (VIVO)
NVS
Novartis AG ADR
$148.19
-1.08%
HEALTHCARE · Cap: $286.46B
VIVO
Meridian Bioscience Inc
$2.24
-5.49%
HEALTHCARE · Cap: $1.49B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 16918% more annual revenue ($56.67B vs $333.02M). NVS leads profitability with a 24.7% profit margin vs 12.8%. VIVO appears more attractively valued with a PEG of 1.33. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
VIVO
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-244.2%
Fair Value
$48.55
Current Price
$148.19
$99.64 premium
Margin of Safety
N/A
Fair Value
$6.53
Current Price
$2.24
$4.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 1.6B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 22.7%
Areas to Watch
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Revenue declined 13.8%
Earnings declined 13.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bull Case : VIVO
The strongest argument for VIVO centers on Price/Book, Operating Margin. PEG of 1.33 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Bear Case : VIVO
The primary concerns for VIVO are P/E Ratio, Market Cap, Revenue Growth.
Key Dynamics to Monitor
NVS profiles as a value stock while VIVO is a declining play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.50 — expect wider price swings.
NVS is growing revenue faster at 2.2% — sustainability is the question.
NVS generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 48/100), backed by strong 24.7% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Meridian Bioscience Inc
HEALTHCARE · PHARMACEUTICALS · USA
Meridian Bioscience, Inc., a life sciences company, develops, manufactures, distributes and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases and elevated blood lead levels worldwide. The company is headquartered in Cincinnati, Ohio.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?